Nathaniel “Ned” David, the co-founder and president of Unity Biotechnology (UBX), is one of biotech’s big idea guys. Before starting Unity in 2011, David founded four other companies that raised $1.5 billion in financing and now employ 400 people. The idea behind Unity is particularly vast: The company is targeting the science around aging, and all the diseases that can result from it.

Its first studies, due to read out over the next few years, are in arthritis and eye diseases like glaucoma and age-related macular degeneration. The goal, David says, is not to extend life, but to increase “healthspan,” the length of time during which people are healthy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy